cougar gold
Selected indexed studies
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. (Lancet Oncol, 2021) [PMID:33845034]
- Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. (Ann Oncol, 2024) [PMID:38369013]
- NTRK gene fusion testing and management in lung cancer. (Cancer Treat Rev, 2024) [PMID:38733648]
_Worker-drafted node — pending editorial review._
Connections
cougar gold helps
Sources
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. (2021) pubmed
- Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. (2024) pubmed
- NTRK gene fusion testing and management in lung cancer. (2024) pubmed
- Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. (2025) pubmed
- Microbiota and free amino acid dynamics during aging of Cougar Gold cheese: insights into the puffy defects. (2026) pubmed
- Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy. (2024) pubmed
- Lithium-Charged Gold Nanoparticles: A New Powerful Tool for Lithium Delivery and Modulation of Glycogen Synthase Kinase 3 Activity. (2026) pubmed
- Integration of Liquid Biopsy for Optimal Management of Non-small Cell Lung Cancer. (2025) pubmed
- Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer. (2025) pubmed
- Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies. (2023) pubmed